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Abstract
Purpose We evaluated whether Gly16Arg beta2-receptor
genotype relates to impulse oscillometry (IOS) in a real-life
clinic setting.
Methods Patients with persistent asthma taking inhaled
corticosteroid ± long-acting beta-agonist (ICS ± LABA)
were evaluated. We compared genotype groups comprising
either no Arg copies (i.e. GlyGly) versus one or two Arg
copies (i.e. ArgArg or ArgGly). IOS outcomes included
total airway resistance at 5 Hz (R5), central airway resis-
tance at 20 Hz (R20), peripheral airway resistance (R5–
R20), reactance at 5 Hz, area under reactance curve (AX)
and resonant frequency (RF). In addition, we recorded
ACQ-5 and salbutamol use.
Results One hundred and twelve ICS-treated asthmatic
patients (mean ICS dose 1238 lg/day), mean age 43 years,
ACQ 2.34, FEV1 82 %, R5 177 % were identified—89
were also taking LABA. 61 patients were GlyGly, while 14
were ArgArg and 37 were ArgGly. There were no signif-
icant differences in IOS outcomes, ACQ or salbutamol use
between the genotypes. The allelic risk (as odds ratio) for
less well-controlled asthma (as ACQ[ 1.5) was 1.1 (95 %
CI 0.72–1.68) in relation to each Arg copy with a corre-
sponding odds ratio for abnormal R5–R20[ 0.07kPA/l.s
being 0.91 (95 % CI 0.57–1.44). 71 % of patients had an
ACQ[ 1.5 in the GlyGly group, versus 67 % in GlyArg/
ArgArg group, with corresponding figures for abnormal
R5–R20[ 0.07 kPa/l.s being 69 versus 73 %.
Conclusion In a real-life clinic setting for patients with
poorly controlled persistent asthma taking ICS ± LABA,
we found no evidence of any relationship of Gly16Arg to
IOS, ACQ or salbutamol use.
Keywords Asthma  Genotype  Beta-2 receptor 
Impulse oscillometry
Introduction
Beta-2 adrenoceptor (b2ADR) allelic polymorphisms at
position 16 (Gly16Arg) may have a clinically important
effect on individual asthmatic patient’s response to beta-
agonist therapy [1]. It has been shown that possession of
the Arg allele results in enhanced down-regulation and
uncoupling of the b2ADR with associated subsensitivity of
response following exposure to regular long-acting b2-
agonist (LABA) therapy in asthmatic patients receiving
concurrent inhaled corticosteroids (ICS) [2]. This subsen-
sitivity of response has been shown to result in loss of
protection against bronchoconstrictor stimuli as well as
worse control for exacerbations [3–5]. For example, in
asthmatic children receiving ICS/LABA, each copy of the
Arg allele is associated with a 1.74-fold increase in risk for
asthma exacerbations [6]. Moreover, among asthmatic
children with the homozygous Arg genotype, control was
better when receiving ICS plus montelukast than with
ICS ? LABA [7].
Other studies have reported no link between Gly16Arg
and pulmonary function outcomes using spirometry or
airway hyper-responsiveness in adult asthmatic patients
These data have been presented in preliminary abstract form at the
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taking ICS/LABA [8–10]. However, impulse oscillometry
(IOS) appears to be more sensitive than spirometry for
detecting bronchodilator responses to b2-agonists in
patients with asthma [11, 12]. IOS is an effort-independent
technique performed during normal tidal breathing which
can be used to ascertain measurements of airway resistance
(R) and reactance (X), in contrast to spirometry which
involves a forced expiratory manoeuvre to measure effort-
dependent lung volumes and flow rates [13]. Moreover,
IOS may be used to assess frequency dependence of
resistance and reactance in central and peripheral airways
[14].
To the best of our knowledge, no study has yet looked at
the putative effect of Gly16Arg on IOS in asthmatic
patients taking ICS/LABA. As a pilot study, we have
therefore performed a retrospective analysis in a real-life
asthma clinic setting where we performed both IOS mea-
surements and Gly16Arg genotyping as part of routine
care. In addition, we also assessed the potential impact of
Gly16Arg upon asthma control using the Juniper asthma
control questionnaire (ACQ) [15].
Patients and Methods
We evaluated n = 112 consecutive ICS-treated non-
smoking asthma patients attending our hospital clinic in
order to analyse their IOS and ACQ score. Patients were
divided into two genotype groups, namely those that do not
possess the Arg polymorphism (n = 61:GlyGly) and those
that possess either one or two Arg copies (n = 14: ArgArg
or n = 37 ArgGly). As part of their routine workup, all
patients had IOS and spirometry performed. Patient
demographics and medications were recorded, as was
asthma control, based on the ACQ questionnaire. Salbu-
tamol use was recorded over the previous week. We rou-
tinely perform Gly16Arg genotyping in our clinic to help
guide asthma management; hence, this audit of routine
clinical care did not require internal review board ethical
approval, although Caldicott guardian approval was
obtained for access to the data. Lung function was mea-
sured on the morning of clinic between 9am and 11am. The
patients had already taken their morning asthma medica-
tions in the usual fashion. The patients all had IOS first,
followed by spirometry.
IOS (Jaeger Masterscreen IOS, Hochberg, Germany)
was performed as previously described [16] in triplicate in
accordance with manufacturer’s guidelines. Resistance at
5 Hz (R5) and 20 Hz (R20) is a measure of total and
central airway resistance, respectively; hence, peripheral
airway resistance was ascertained by the difference
between R5 and R20. Reactance at 5 Hz (X5) and the area
under the reactance curve (AX) were also measured.
A SuperSpiro spirometer (Micro Medical Ltd, Chatham,
Kent, United Kingdom) was used to perform spirometry in
triplicate in accordance with European Respiratory Society
guidelines [17]. Beta-2 adrenoceptor genotype was assayed
using a previously validated assay [6].
Statistical Analysis
Unpaired students t test or analysis of variance was used to
compare normally distributed continuous variables,
whereas the Mann–Whitney or Kruskal–Wallis test was
used for non-normally distributed continuous variables. We
compared two genotype groups comprising either no Arg
copies (GlyGly) versus one or two copies (GlyArg or
ArgArg). Binary logistic regression was used to calculate
odds ratios for asthma that was not well controlled (i.e.
ACQ[ 1.5) as well as abnormal peripheral airway resis-
tance as R5–R20[ 0.07 kPa/l.s [16], in relation to each
Arg allele. Statistical significance for all analyses was set at
P\ 0.05 (2-tailed). SPSS statistical software, version 21
(SPSS Inc., Chicago, Illinois) was used for all analyses.
Results
A total of 112 ICS-treated persistent asthmatic patients
were analysed. The mean age of patients was 43 years and
most of our patients (99 %) were Caucasian. Mean FEV1
was 82 % predicted, mean R5 177 % predicted, mean ACQ
was 2.34, mean ICS dose was 1238 lg (beclomethasone
equivalent dose), 80 % of patients were on a LABA and
36 % were on LTRA. The mean ICS dose was 1353 and
786 ug, respectively, for patients taking ICS/LABA and
ICS alone (P\ 0.0001). Genotype frequencies were as
follows: GlyGly 54.5 %, ArgGly 33 %, ArgArg 12.5 %.
Among all 112 ICS-treated patients, there was no sig-
nificant difference in patient demographics between the
genotype groups, aside from ICS dose. The mean ICS
doses (beclomethasone equivalent) were 1136 and 1358 lg
for GlyGly and ArgArg/ArgGly respectively (P = 0.04).
Despite the lower ICS dose in the GlyGly patients, there
were no significant differences in any IOS outcomes, ACQ
or salbutamol use between the two groups (Table 1). We
also separately compared homozygous genotypes (i.e.
without the heterozygotes) which showed no differences
(ArgArg vs. GlyGly): R5 0.57 versus 0.60 kPa/l.s P = 0.7,
R20 0.41 versus 0.43 kPa/l.s P = 0.35, AX 1.39 versus
1.56 kPa/l P = 0.32, ACQ 2.87 versus 2.34 P = 0.16,
Salbutamol use: 8.5 versus 6.5 puffs/day P = 0.16. The
odds ratio per copy of Arg for poor asthma control (as
ACQ[ 1.5) was 1.1 (95 % CI 0.72–1.68) and for
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abnormal R5–R20[ 0.07 kPa/l.s was 0.91 (95 % CI
0.57–1.44). 71 % of patients had an ACQ[ 1.5 in the
GlyGly group, versus 67 % in GlyArg/ArgArg group, with
corresponding figures for abnormal R5–R20[ 0.07 kPa/l.s
being 69 versus 73 % (Fig. 1).
When the data were filtered for LABA users (n = 89/
112), there were also no significant differences in any
outcomes when comparing ArgArg/ArgGly (n = 42) ver-
sus GlyGly (n = 47) groups: R5 0.56 versus 0.57 kPa/l.s
P = 0.91, R20 0.42 versus 0.43 kPa/l.s P = 0.87, R5–R20
0.14 versus 0.15 kPa/l.s P = 0.16, AX 1.35 versus
1.50 kPa/l P = 0.45, ACQ 2.25 versus 2.37 P = 0.67 and
salbutamol use 6.1 versus 6.5 puffs/day P = 0.73. How-
ever, for the R5–R20 those taking ICS/LABA had lower
value compared to ICS alone: 0.15 versus 0.23 kPa/l.s
P = 0.03. Spirometry variables were non-significant
comparing ICS/LABA versus ICS alone; FEV1 % pre-
dicted 82 versus 80 % P = 0.65, FEF25-75 % predicted
51.6 versus 47.9 % P = 0.6. For homozygous genotypes in
ICS/LABA users (ArgArg n = 11 vs. GlyGly n = 47),
there were also no significant differences: R5 0.57 versus
0.60 kPa/l.s P = 0.70, R20 0.41 versus 0.43 kPa/l.s
P = 0.73, AX 1.39 versus 1.56 kPa/l P = 0.75, ACQ 2.87
versus 2.34 P = 0.16 and salbutamol use 8.54 versus 6.52
puffs/day P = 0.16. The odds ratio per Arg copy for
ACQ[ 1.5 among ICS/LABA users was 1.34 (95 % CI
0.87–2.06) and for abnormal R5–20[ 0.07 kPa/l.s was 1.1
(0.70–1.75 95 % CI).
Discussion
The results of the present study demonstrated no significant
difference in IOS outcomes in relation to the Gly16Arg
polymorphism in ICS-treated persistent adult asthmatics in
a real-life clinic setting. Furthermore, there was also no
difference in salbutamol use or asthma control between
genotypes. These findings were replicated in a subgroup
analysis of those patients who were taking ICS/LABA.
This observation is in contrast to previous studies in asth-
matic children, which have identified an increased risk of
exacerbation in individuals exposed to regular ICS/LABA
who possess one or more copies of the Arg allele [5, 6]. We
Table 1 Outcome comparisons
between genotypes (means and
95 % CI) for all ICS-treated
patients
GlyGly (n = 61) GlyArg/ArgArg (n = 51) P
R5 (kPa/l.s) 0.60 (0.54–0.67) 0.58 (0.52–0.65) 0.69
R20 (kPa/l.s) 0.43 (0.39–0.47) 0.44 (0.39–0.48) 0.78
R5–R20 (kPa/l.s) 0.17 (0.13–0.22) 0.15 (0.12–0.18) 0.38
X5 (kPa/l) -0.27 (-0.63–0.10) -0.13 (-0.34–0.08) 0.38
AX (kPa/l) 1.56 (1.09–2.03) 1.31 (0.95–1.68) 0.42
RF (Hz) 17.6 (15.9–19.2) 16.66 (15.1–18.3) 0.43
ACQ5 2.34 (2.02–2.65) 2.34 (1.95–2.73) 0.99
Salbutamol (puffs/day) 6.5 (5.3–7.7) 6.41 (5.0–7.9) 0.91
FEV1(l) 2.48 (2.27–2.71) 2.40 (2.19–2.61) 0.58
Fig. 1 Scatter plot of individual values for ACQ-5 and R5–R20
along with means and 95 % CI for genotypes containing no Arg
copies (GlyGly) and either one or two Arg copies (GlyArg/ArgArg).
For ACQ, the interrupted lines show cutoffs for optimal control
(\0.75) and poor control ([1.5). For R5–R20, the interrupted line
depicts abnormal values [0.07 kPa/l.s. Open symbols depict ICS
without LABA, while closed symbols depict ICS with LABA
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believe that our real-world clinic patients were a strength of
the study, as such patients tend to be excluded from
prospective randomized controlled trials due to unrealistic
inclusion and exclusion criteria. Thus, we did not select out
particular phenotypes who, for example, were required to
exhibit marked salbutamol reversibility, as has been the
case in several previous studies where there has been a
clear a prior bias towards beta-agonist responders [8, 9].
The ACQ7 score includes input for both reliever use as
well as FEV1 % predicted. We elected to use ACQ5 for
this study since concomitant LABA exposure might
potentially confound ACQ scoring due to concomitant
effects on reliever use as both long- and short-acting beta-
agonists act on the same receptor. At the same time, we
considered that including FEV1 % might also influence the
overall ACQ score due to the bronchodilator effects of
LABA. Pointedly, the ACQ-5 score has been shown to be
usable in clinical trials without loss of validity compared to
ACQ7 [15]. The minimal important difference in ACQ is
0.5, while the optimal cut points for well-controlled and
inadequately controlled asthma are 0.75 and 1.5, respec-
tively [18]. The mean ACQ score of 2.34 in our study
exceeded the optimal cutoff of 1.5 for identifying poor
asthma control [18] with 69 % of all patients having values
higher than this cutoff. Despite having a relatively pre-
served mean FEV1 of 82 %, our patients exhibited a high
total airway resistance (R5) of 177 % as well as a high
peripheral airway resistance (R5–R20) of 0.16 kPa/l.s. This
along with a mean ICS dose of 1238 lg/day with most
patients taking ICS/LABA and at least 6 puffs/day of
reliever use would indicate that our cohort had moderate to
severe persistent asthma in keeping with a secondary care
setting.
As this was a pilot study, we only captured cross-sec-
tional data from one clinic visit, and did not assess vari-
ability over time, which is the hallmark of patients with
persistent asthma. Moreover, we did not evaluate treatment
compliance and so we can only assume that patients were
taking what was recorded in the notes at the time of the
clinic visit. We appreciate the small number of individuals
possessing the homozygote Arg genotype which limited
our analysis when comparing homozygous genotypes
(n = 14 vs. n = 61). Nonetheless, when we analysed the
data among all patients looking at the attributable risk of
each Arg copy according to poor asthma control
(ACQ[ 1.5), we found an odds ratio of 1.1 (95 % CI
0.72–1.68) and for abnormal R5–R20[ 0.07kPA/l.s an
odds ratio 0.91 (0.57–1.44).
Studies have shown corticosteroids may reverse b2ADR
down-regulation and associated subsensitivity of response
in asthmatics taking regular LABA [19, 20]. Considering
all of our patients were taking ICS with a mean
beclomethasone equivalent dose of 1238 lg/day, this may
have obviated any potential differences in IOS between
genotypes in ICS/LABA-treated patients. One advantage of
IOS is that it can be used to evaluate the smaller airways
using frequency-dependent measures such as peripheral
airway resistance (R5–R20). In this regard, when inspect-
ing the scatter plot, we identified a high proportion (71 %)
of patients with abnormal R5–R20 values above 0.07 kPa/
l.s, although there were no differences between genotypes.
In conclusion, our real-world pilot study demonstrated
no significant impact of Gly16Arg upon IOS outcomes,
salbutamol use or asthma control, in adults with persistent
asthma. Further large-scale studies are required to evaluate
the impact of Gly16Arg genotype on serial IOS measure-
ments over time, perhaps comparing cohorts with and
without LABA therapy.
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